X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2) 2
index medicus (2) 2
1st-line treatment (1) 1
a-beta immunotherapy (1) 1
aged (1) 1
antibodies - blood (1) 1
antibodies - immunology (1) 1
antibodies - metabolism (1) 1
apoptosis-inducing ligand (1) 1
bevacizumab (1) 1
biochemical research methods (1) 1
cad106 (1) 1
cancer research (1) 1
chemical and drug induced liver injury - etiology (1) 1
chemistry, analytical (1) 1
cohort studies (1) 1
combination (1) 1
conatumumab (1) 1
death (1) 1
dose-response relationship, drug (1) 1
dr5 receptor (1) 1
enzyme-linked immunosorbent assay (1) 1
enzymes (1) 1
freezing (1) 1
hepatotoxicity (1) 1
human hepatocytes (1) 1
immunogenicity (1) 1
immunoglobulin g - blood (1) 1
immunoglobulin g - immunology (1) 1
immunoglobulin g - metabolism (1) 1
immunoglobulin m - blood (1) 1
immunoglobulin m - immunology (1) 1
infusions, intravenous (1) 1
lexatumumab (1) 1
liver (1) 1
medicine & public health (1) 1
middle aged (1) 1
nanobody (1) 1
neoplasms - blood (1) 1
neoplasms - drug therapy (1) 1
neoplasms - immunology (1) 1
oncology (1) 1
outsourced services (1) 1
pharmacology & pharmacy (1) 1
pharmacology/toxicology (1) 1
protein stability (1) 1
receptors, tnf-related apoptosis-inducing ligand - immunology (1) 1
recommendations (1) 1
safety (1) 1
single-domain antibodies - administration & dosage (1) 1
single-domain antibodies - adverse effects (1) 1
single-domain antibodies - blood (1) 1
single-domain antibodies - immunology (1) 1
tas266 (1) 1
temperature (1) 1
time factors (1) 1
trail (1) 1
vaccination (1) 1
vaccines - immunology (1) 1
validation (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 05/2015, Volume 75, Issue 5, p. 887
  TAS266 is a novel agonistic tetravalent Nanobody^sup ^ targeting the DR5 receptor. In preclinical studies, TAS266 was more potent than a cross-linked DR5... 
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 05/2015, Volume 75, Issue 5, pp. 887 - 895
Purpose: TAS266 is a novel agonistic tetravalent Nanobody super( registered ) targeting the DR5 receptor. In preclinical studies, TAS266 was more potent than a... 
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 05/2015, Volume 75, Issue 5, p. 887
Adult patients with advanced solid tumors were to receive assigned doses of TAS266 (3, 10, 15, or 20 mg/kg) intravenously on days 1, 8, 15, and 22 of a 28-day... 
Enzymes | Liver
Journal Article
Bioanalysis, ISSN 1757-6180, 2014, Volume 6, Issue 10, pp. 1395 - 1407
Background: To generate exhaustive data on the stability of human anti-immunotherapeutic antibodies. Materials & methods: Samples collected from over 100... 
VALIDATION | CHEMISTRY, ANALYTICAL | CAD106 | RECOMMENDATIONS | A-BETA IMMUNOTHERAPY | BIOCHEMICAL RESEARCH METHODS
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.